Literature DB >> 7105380

Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.

B T Hill, R D Whelan.   

Abstract

Clinical evidence suggests some lack of cross resistance between vincristine (VCR) and vindesine (VDS). To investigate this phenomenon experimentally, drug-resistant L5178Y lymphoblast cell lines have been derived in vitro. These lines, under conditions of continuous drug exposure, exhibit a 50-fold order of resistance. Resistance appears due, at least in part, to impaired cellular drug accumulation and retention. Exposure of these resistant cells to VCR or VDS for 24 h showed that the presence or absence of cross resistance was dose-dependent, being most noticeable at low concentrations (less than 0.5 ng/ml) and absent at higher drug levels. Cross resistance also showed some dose-dependency for vinblastine and formyl-leurosine, but this was not seen with other drugs. Marked and complete cross resistance at all concentrations tested was noted with adriamycin and 4'-epiadriamycin in both resistant lines, which, however, retained the same sensitivities as the parent line to VM26, VP-16-213, 5-fluorouracil, and methotrexate. Responses to actinomycin D and mAMSA differed in these two resistant lines. VDS-resistant cells exhibited cross resistance to both drugs, whilst VCR-resistant cells showed only slight resistance to actinomycin D whilst retaining full sensitivity mAMSA. This observation that cross resistance between VCR and VDS is not invariable in vitro appears to reflect clinical experience.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105380     DOI: 10.1007/BF00255477

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Uptake and binding of vincristine by murine leukemia cells.

Authors:  W A Bleyer; S A Frisby; V T Oliverio
Journal:  Biochem Pharmacol       Date:  1975-03-01       Impact factor: 5.858

2.  Studies in histochemistry. I. Determination of nucleic acids in microgram amounts of tissue.

Authors:  J F SCOTT; A P FRACCASTORO; E B TAFT
Journal:  J Histochem Cytochem       Date:  1956-01       Impact factor: 2.479

3.  The value of adriamycin in overcoming resistance to methotrexate in tissue culture.

Authors:  B T Hill; L A Price; J H Goldies
Journal:  Eur J Cancer       Date:  1976-07       Impact factor: 9.162

4.  Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.

Authors:  M Bayssas; J Gouveia; P Ribaud; M Musset; F de Vassal; J L Pico; L de Luca; J L Misset; D Machover; D Belpomme; L Schwarzenberg; C Jasmin; M Hayat; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Antitumor activity of deacetyl vinblastine amide sulfate (vindesine) in rodents and mitotic accumulation studies in culture.

Authors:  M J Sweeney; G B Boder; G J Cullinan; H W Culp; W D Daniels; R W Dyke; K Gerzon; R E McMahon; R L Nelson; G A Poore; G C Todd
Journal:  Cancer Res       Date:  1978-09       Impact factor: 12.701

6.  Phase I and II studies of vindesine.

Authors:  M Valdivieso
Journal:  Cancer Treat Rev       Date:  1980-09       Impact factor: 12.111

7.  An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood.

Authors:  W Krivit; R Chilcote; A Pyesmany; J Anderson; D Hammond
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Lethal and kinetic effects of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine).

Authors:  B T Hill
Journal:  Eur J Cancer       Date:  1980-01       Impact factor: 9.162

9.  Experimental in vivo cross-resistance of vinca alkaloid drugs.

Authors:  R Maral; C Bourut; E Chenu; G Mathe
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.

Authors:  G Mathé; J L Misset; F De Vassal; J Gouveia; M Hayat; D Machover; D Belpomme; J L Pico; L Schwarzenberg; P Ribaud; M Musset; C Jasmin; L De Luca
Journal:  Cancer Treat Rep       Date:  1978-05
View more
  10 in total

1.  Spirogermanium--a novel antitumour agent expressing a lack of cross-resistance in vitro with a range of 'standard' antitumour drugs.

Authors:  B T Hill; R D Whelan
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

2.  Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.

Authors:  M P Rivera-Fillat; J Pallarés-Trujillo; C Domènech; M R Grau-Oliete
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

3.  Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

Authors:  B T Hill; L Y Dennis; X T Li; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro.

Authors:  E M Gibby; O Boyse; B T Hill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Vindesine/cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung.

Authors:  N Niederle; J Schütte; W Krischke; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1984-08-16

6.  Decreased retention of vinca alkaloids in chronic lymphatic leukemia cells from refractory patients.

Authors:  M Beksac; C Peterson; P Reizenstein
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro.

Authors:  B T Hill; L K Hosking; S A Shellard; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 8.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.

Authors:  C Etievant; J M Barret; A Kruczynski; D Perrin; B T Hill
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

10.  Characterization of an etoposide-resistant human K562 cell line, K/eto.

Authors:  I Sugawara; T Iwahashi; K Okamoto; Y Sugimoto; H Ekimoto; T Tsuruo; T Ikeuchi; S Mori
Journal:  Jpn J Cancer Res       Date:  1991-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.